Kornimate/medical-research-clean huggingface dataset:
perceptions of cervical cancer among asian americans

Conditions: Epidemiology

Summary: the goal of this research study is to learn about the beliefs, practices, and knowledge about cervical cancer among asian american young adults. researchers want to develop materials that will educate asian americans about cervical cancer and encourage them to get screened for this disease.

survey: if you agree to take part in this study, you will complete a survey about your health practices and knowledge about cervical cancer and hpv. you will also be asked to provide some personal history on yourself such as your age, gender, birthplace, ethnicity, relationship status and educational level. female participants will be asked to indicate if they have received an hpv test (also called a "pap" test) within the last 3 years. the survey will take about 5-10 minutes to complete and will be filled out on the same day as the focus group. focus group: you will also take part in a discussion group called a "focus group." a trained focus group leader will guide you and 8-10 others through a series of questions. he/she will lead a discussion to hear comments, opinions, and observations on a brochure and poster about cervical cancer and hpv. groups will be made up of participants of the same gender (that is, all male or all female) and ethnic group (filipino, korean, or vietnamese). each discussion group will last about 2 hours and may be audiotaped so that the discussion may be transcribed and analyzed. you will only be called by your first name and you are not required to use your real name during the focus group discussion. you will not be identified by the audiotape recordings. length of study: when the focus group discussion is over, you will be off-study. this is an investigational study. up to 60 participants will be enrolled on this study. all will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: 1. self identified as korean, filipino, or vietnamese 2. individuals 18-29 years of age 3. have a high school education or less (but not less than 4th grade) 4. able to read and speak english and one of these languages: korean, vietnamese, or tagalog 5. lower socioeconomic status, defined as: for a household of 1, not more than $18,620 annual income, for a household of 2, not more than $24,980, for a household of 3, not more than $31,340, for a household of 4, not more than $37,700, for a household of 5, not more than $44,060, for a household of 6,not more than $50,420, for a household of 7, not more than $56,780 note: the cdc has granted some flexibility with these income guidelines 6. not currently pregnant exclusion criteria: 1) household income greater than 200% of the federal poverty level

Keywords: epidemiology cervical cancer human papillomavirus focus group questionnaire survey hpv
the effect of mother's voice on the levels of pain and comfort in newborns

Conditions: Newborns

Summary: this study was conducted in a randomized controlled experimental type to determine the effect of maternal voice during care on pain and comfort level in term newborns receiving mechanical ventilation. the sample of the study was consisted of 60 term newborns receiving mechanical ventilation who were hospitalized in the 7-bed neonatal intensive care unit of a private hospital in istanbul in accordance with the selection criteria. introductory information form, vital signs follow-up form, neonatal comfort behavior scale and neonatal pain scale (npass) forms prepared by the researchers were used as data collection tools.

intervention group: during the care, from the beginning to the end, mother's voice was played to the newborns. it took about 20 minutes. the mini bluetooth speaker and the decibel meter were disinfected with the rapid surface disinfectant used in the clinic. the speaker was placed 30 cm away from the infant's ear and the sound level in the incubator was adjusted to be 50-60 db by using a decibel meter mother's voice was played from the beginning of the provision of care and continued for 15 minutes after the end of the provision of care. during the provision of care, comfortneo scores, pain scores, and vital signs were measured and recorded on the vital signs follow-up form. control group: standard nursing care lasting 20 minutes was performed in the routine sound environment of the neonatal intensive care unit. comfortneo scores, pain scores, and vital signs were measured and recorded on the vital signs follow-up form.

Eligibility criteria:
inclusion criteria: * connected to a mechanical ventilator (intubation or nasal cpap), * term newborns (born at 37-42 weeks), * no neurological disorders, * no congenital or acquired hearing malformations, * the family consents for their infant to participate in the study, exclusion criteria: * diagnosis of asphyxia, * use of sedatives or analgesics, * congenital anomaly, * underwent an extra invasive procedure or surgical intervention, * parents with congenital hearing problems.

Keywords: comfort, mechanical ventilatör, mother's voice, newborn, pain
mechanistic study of ocrevus

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to investigate the immune cell and other factor changes with ocrevus in multiple sclerosis (ms) patients. researchers will recruit 35 participants for this study. patients will be enrolled from the multiple sclerosis center at the university of michigan health system in ann arbor. the goal of the study is to understand the role of regulatory b cell, t cell and other factors in mediating the therapeutic effects of ocrevus.


Eligibility criteria:
inclusion criteria: patients with ms either with relapsing or primary progressive course; who are newly starting on ocrelizumab (ocrevus) at the time of enrollment or healthy controls who do not have a significant medical conditions such as cancer, chronic infection, or autoimmune disease, have not taken steroids in the past 2 months, and who are not on an immune suppressant medication. * ability to give informed consent * willing to have blood drawn as scheduled in the protocol * willing and able to complete all procedures and evaluations related to the study exclusion criteria: * medical or psychiatric conditions that may affect the patient's ability to give informed consent * has received an experimental drug within 30 days of enrollment * concomitant other disease modifying medications (such as rebif, betaseron, avonex, copaxone, gilenya, tecfidera, aubagio, mayzent, mavenclad, alemtuzumab, methotrexate, azathioprine, novantrone, cyclophosphamide, cyclosporine, tysabri, rituxan, ocrevus, etc.) * has any contraindication to high-dose immunotherapy, including pregnancy, trying to become pregnant, or breast feeding during the study * active hepatitis b virus infection * history of life-threatening infusion reaction to rituxan or ocrevus * chronic infection or any severe acute infection within 3 months prior to screening

Keywords: ocrevus b cell t cell cytokines
dose clinical trial of guanfacine extended release for the reduction of aggression and self-injuries behavior associated with prader-willi syndrome

Conditions: Prader-Willi Syndrome

Summary: this is a placebo-controlled clinical trial to assess the utility of guanfacine extended release (gxr) in the management of patients with prader willi syndrome (pws) who have significant aggression or self-injury. the purpose of this trial is to establish the safety of gxr with a specific focus on metabolic effects.

prader-willi syndrome is a genetic disorder due to loss of function of specific genes. in newborns, symptoms include weak muscles, poor feeding, and slow development. beginning in childhood, the person becomes constantly hungry, which often leads to obesity and type 2 diabetes. also, mild to moderate learning disability and behavioral problems are typical. guanfacine extended release (gxr), the investigational drug in this study would be the first study to evaluate the drug in patients with prader willi syndrome. "investigational" means it is not approved by the food and drug administration (fda) to treat prader willi syndrome. however, guanfacine extended released (gxr) is an fda approved drug used to treat children and adolescents with hypertension and attention deficit hyperactivity disorder (adhd). gxr is thought to respond to parts of the brain that lead to strengthening working memory, reducing distraction, improving attention and impulse control. gxr is generally considered safe for children as long as it is used according to the dosing instructions (up to 4mg) of a qualified medical professional.

Eligibility criteria:
inclusion criteria: * 6 and 35 years of age * diagnosis of pws confirmed by genetic testing. * rating of moderate or above on the clinical global impression- severity scale will be required for entry. exclusion criteria: * subjects with a positive pregnancy test, swallowing difficulty, and/or presenting with active psychosis or mania will be excluded. * individuals with pre-existing, clinically significant bradycardia (\< 8 years: \<64 bpm; 8 to 12 years: \<59 bpm; 12 to 16 years: \<53 bpm) or hypotension, defined as 5th percentile for height and gender,26 will be excluded from the study. * subjects receiving antipsychotic medications due to a documented history of psychosis or bipolar disorder will be allowed to continue taking the medication without dosage modification. * growth hormone, thyroid hormone replacement treatment, and non-psychiatric medicines will be allowed to continue. * n-acetyl cysteine and anticonvulsant medication (only if prescribed for seizures) will be allowed to continue, with specific instructions to not make any dosage changes during the clinical trial.
manage-vt registry - management of ventricular tachycardia outcomes registry

Conditions: Ventricular Tachycardia

Summary: data collection registry for patients with ventricular tachycardia to help physicians give better care for patients clinically and procedurally.

after consent from a patient the research team will input patients data from many different categories. there is a link to the pdf for the consent form, a patients anticoagulant medications will be assessed, their ventricular tachycardia (vt) history will be inputted, and their date of birth and zip code will inputted. the research team will then input any ekg's, echocardiograms, vt ablations, icd's, s-icd's, lab results, and comorbidities.

Eligibility criteria:
inclusion criteria: * must be at least 18 years old * must not be exclusion criteria: -

Keywords: ventricular arrhythmia ventricular tachycardia ventricular fibrillation stroke
new coating for urinary intermittent catheters

Conditions: Retention, Urinary

Summary: the goal is to confirm, that the newly developed coating is non-inferior to the comparator with respect to the overall discomfort of the catheterisation (assessed by participant). participants will attend 3 study site visits and will be catheterised by a hcp at visit 1 and 2 with one of the two catheters in randomisation order. urine samples will be collected pre- and post catheterisation for assessments.

the primary objective of the study is to confirm that the newly developed investigational coating is non-inferior to the comparator coating with respect to the overall discomfort of catheterisation. the investigational device is a ready-to-use, sterile, hydrophilic-coated nelaton male catheter for intermittent catheterisation and based on the standard speedicath® male intermittent catheter with a difference in the composition on the coating. the study is a double-blinded, randomized, crossover study including 32 randomized healthy male volunteers. the total study duration for the individual subject will be between 4-21 days and consists of 3 site visits v0, v1 and v2, and v0 andv1 can be combined at v1 and v2 the subjects will be catheterized in a hospital setting by a health care professional, with one of the two catheters in a randomized order. subject will be asked to assess the overall discomfort of the catheterisation on vas.

Eligibility criteria:
inclusion criteria: 1. has given written informed consent 2. is at least 18 years old 3. has full legal capacity 4. has self-assessed intact male anatomy with no abnormalities or disease of the lower urinary tract or any surgical procedures performed in the lower urinary tract 5. is able (assessed by investigator) and willing to adhere to study procedures during study duration. 6. is able to refrain from using analgesics up to 24 hours prior to catheterisation visits 7. is negative for haematuria, measured by urine dipstick test of erythrocytes exclusion criteria: 1. is participating in any other clinical investigation during this investigation, which could affect the results of this investigation, as assessed by investigator. 2. has previously been randomized in this investigation. 3. has known hypersensitivity towards any of the devices used in the investigation 4. is currently experiencing symptoms associated with uti, as assessed by investigator. 5. has known impaired sensation of the urethra
prospective epidemiological study of the prevalence of hlab*5701 in hiv-1 infected patients

Conditions: Infection, Human Immunodeficiency Virus

Summary: this study is a cross sectional observational study to evaluate the prevalence of hla-b\*5701 in the major french ethnotypes. any hiv-1 infected subject will be eligible for this study including antiretroviral therapy (art) naã-ve and experienced subjects irrespective of abacavir use, as well as subjects previously tested for hla-b\*5701. subjects will be approached during a standard clinic visit, and all subjects will be consented prior to any study specific procedure. subjects will be asked to provide a tissue sample (cheek cells and blood sample) which will be used to assess hla-b\*5701 status by central and local methodologies.


Eligibility criteria:
inclusion criteria: * hiv-1 infected patients, art naive or experienced over the age of 18 years. * patients must be either affiliated to or beneficiary of a social security category. * patient is willing and able to understand and provide written informed consent prior to participation in this study. exclusion criteria: * none

Keywords: human immunodeficiency virus hlagenetics polymorphism
sucrose analgesia in infants undergoing casting for club foot

Conditions: Clubfoot

Summary: babies with congenital clubfeet are treated by the ponseti casting method. the procedure may cause discomfort to the patient. this study will examine the use of 5 cc sucrose solution as a comforting agent for the babies.

babies who were born with congenital clubfeet are currently being treated by the conventional ponseti method. this procedure is done in an outpatient clinic setup. the procedure is painless but may cause some discomfort to the patient. this study will examine the use of 5 cc sucrose solution as a comforting agent for the babies. the control group will consist of patients who will get 5cc saline pre cast application, while the study group will be given 5cc of sucrose solution. patients and physicians are blinded to the treatment they get. outcome measures will include pulse rate and oxygenation as an accepted measure of discomfort.

Eligibility criteria:
inclusion criteria: * all otherwise healthy babies who need casting for congenital clubfeet exclusion criteria: * all non idiopathic conditions for clubfoot, all individuals who have any kind of known systemic illness, all babies born to diabetic mothers.

Keywords: clubfoot casting ponseti discomfort
pilot study of a mind diet intervention in women undergoing active treatment for breast cancer

Conditions: Breast Cancer

Summary: breast cancer (bc) is the most frequently diagnosed cancer in women. systemic cancer treatments are an important contributor to dramatic improvements in the long-term survival of women with bc. however, cancer treatment can lead to cognitive impairment and declines in quality of life in women with bc. many cancer survivors experience memory and brain function decline following chemotherapy which can last for years. a newer diet pattern, mediterranean-dash \[dietary approaches to stop hypertension\] intervention for neurodegenerative delay (mind), was shown to help with protecting brain functions. the mind diet is high in anti-inflammatory nutrients (e.g., omega-3 polyunsaturated fatty acids (pufas), carotenoids, b-vitamins, and polyphenols) and limits the intake of brain-unhealthy foods (i.e., butter/margarine, cheese, red meat, fried foods, pastries, and sweets), which may help alleviate negative cognitive outcomes from cancer treatments. this randomized controlled trial aims to investigate the effect of the mind diet on cognitive functions in women with invasive bc starting systemic therapies.


Eligibility criteria:
inclusion criteria: * stage ii-iv hormone receptor+, breast cancer diagnosis * post-menopausal (defined as at least 1-year post menses, on ovarian suppression medication, or s/p oophorectomy) * within +/- 4 weeks of starting initial systemic therapies (e.g. chemotherapy, targeted therapies, endocrine therapy) * english speaking exclusion criteria: * history of dementia, stroke, traumatic brain injury, brain metastasis or other conditions that could lead to cognitive impairment * mind diet score \>8 * unwilling/unable to eat \>2 types of mind food * receiving insulin therapy for diabetes * diagnosis of triple negative breast cancer * unable to give informed consent.
cognitive assessment tools for huntington's disease.

Conditions: Huntington Disease

Summary: the purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in huntington disease (hd) clinical trials that might be useful both for initial screening and for clinical trial application. one is the coding test and the other is the self-administered gerocognitive examination (sage). both the coding test and the sage have been used for assessments of individuals with other neurodegenerative diseases, including alzheimer's disease, parkinson's disease and lewy body disease, but data is lacking on their use in individuals with hd.

subjects will be recruited from the osu wexner medical center huntington society of america center of excellence clinic. subjects will be scheduled for a one-time visit to complete the study. the entire visit will take approximately 1-1.5 hours. vital signs (weight, blood pressure, temperature, respiratory rate and pulse) will be conducted. the subject's medical records will be reviewed to obtain their demographics, current medications, medical/surgical/ hd family history, and hd diagnosis details. if any adverse events occur during the research visit they will be documented. participants will complete cognitive, functional and motor assessments.

Eligibility criteria:
inclusion criteria: 1. males and females aged 30-65 (inclusive) at the time of signing the informed consent form. 2. genetic diagnosis of hd as defined by a cag repeat size ≥ 40. 3. a clinical diagnosis of hd as defined by a diagnostic confidence level (dcl) of 4. 4. vision and hearing sufficient for compliance with tests. 5. on a stable dose of medications for 30 days prior to the time of signing the informed consent form. exclusion criteria: 1. age of symptom onset less than 19 years old or greater than 60 years old. 2. any serious neurological disorder aside from hd, including but not limited to alzheimer's disease, parkinson's disease, frontotemporal dementia, lewy body dementia, amyotrophic lateral sclerosis, traumatic brain injury... etc. that in the opinion of the investigator is clinically significant. 3. any ongoing serious medical condition that in the opinion of the investigator is clinically significant. this includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure). 4. subjects who are pregnant or breast feeding 5. subjects with a history of a learning disability. 6. subjects who are unable to provide consent.

Keywords: self-administered gerocognitive examination (sage) coding huntington disease
efficacy of alkalinized lidocaine in the endotracheal tube cuff on the incidence of coughing during emergence

Conditions: Cough; Anesthesia

Summary: this study is designed to compare the efficacy of endotracheal tube cuffs pre-filled with alkalinized lidocaine on the: * incidence of coughing during emergence of general anesthesia * time needed for emergence following a desflurane-based anesthesia * incidence of sore throat after extubation. the investigator's hypothesis is that the use of endotracheal tube cuffs pre-filled with alkalinized lidocaine will reduce the incidence of coughing by 50% relative to a control group following a desflurane-based anesthesia.

emergence is an important period of general anesthesia during which several problems can occur. coughing, hypertension, tachycardia and agitation have been observed during emergence of general anesthesia. desflurane is a newer volatile agent allowing early recovery from anesthesia. this agent has led to earlier discharge and more rapid resumption of normal activities after surgery. however, an incidence of coughing around 70% has been reported after a desflurane-based anesthesia. different techniques and drugs have been studied to reduce coughing during emergence. among others, the role of lidocaine given intravenously, topically, or intracuff has been studied. intracuff lidocaine has been shown to increase the tolerance to the endotracheal tube without reducing the swallowing reflex. however, lidocaine slowly diffuses across the tube's cuff. the addition of bicarbonates is required to increase its diffusion to the underlying tracheal tissue. alkalinization of lidocaine allows the diffusion of 65% of its neutral base form over a period of 6 hours. in vitro studies have demonstrated that the optimal time for local anesthetic diffusion through the cuff may vary from 90 to 180 minutes. due to its low onset, this technique would be appropriate for long-duration surgeries. pre-filling the endotracheal tube cuffs with alkalinized lidocaine at least 90 minutes before intubation could be appropriate for surgeries expected to last less than two hours. this study will assess the efficacy of pre-filling endotracheal tube cuffs with alkalinized lidocaine to prevent coughing during emergence in short-duration surgeries.

Eligibility criteria:
inclusion criteria: * patients undergoing elective short-duration surgery under general anesthesia (expected duration of less than 2 hours) * physical status 1-3 exclusion criteria: * asthma or severe pulmonary disease * pulmonary tract infection * anticipated difficult intubation * current use of cough medicine * contraindication to lidocaine * pregnancy * airway surgery * inability to provide informed consent * patient refusal